STOCK TITAN
  1. Home
  2. News
  3. COCP

Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets’ 17th Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time).

The live presentation will be available at www.noblecon17.com. A high-definition video webcast of the presentation will be available beginning January 20, 2021 on the Investors section of the Cocrystal website here.

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

# # #


Stock COCP logo
Cocrystal Pharma, Inc.

NASDAQ:COCP

COCP Rankings

#5244 Ranked by Market Cap
#4067 Ranked by Stock Gains
N/A Ranked by Dividends

COCP Latest News

May 1, 2024
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Mar 28, 2024
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Mar 19, 2024
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Mar 5, 2024
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
Jan 4, 2024
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

COCP Stock Data

16.38M
7.11M
30.03%
6.72%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOTHELL

About COCP

cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.